Relevant bibliographies by topics / Cancer ratio plus

Contents

  1. Journal articles
  2. Book chapters
  3. Conference papers
  4. Reports

Academic literature on the topic 'Cancer ratio plus'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer ratio plus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer ratio plus"

1

International, Journal of Medical Science and Innovative Research (IJMSIR). "A Cross Sectional Study to Determine The Efficacy of Serum LDH: Pleural Fluid Ada Ratio As A Biomarker of Malignant Pleural Effusion in IRD, SMS Medical College, Jaipur." International Journal of Medical Science and Innovative Research (IJMSIR) 9, no. 4 (2024): 151–58. https://doi.org/10.5281/zenodo.15422923.

Full text
Abstract:
<strong>Abstract</strong> <strong>Introduction</strong>: The malignant pleural effusion is one of the most common causes of exudative pleural effusion. There is no accurate and commonly accepted biochemical marker of MPE, hence using common parameters two ratio serum LDH: pleural fluid ADA (cancer ratio) and cancer ratio: pleural fluid lymphocyte count (cancer ratio plus) derived and their efficacy in identification of MPE is studied. <strong>Methods</strong>: 60 undiagnosed pleural effusion patients were studied in a hospital based cross sectional observational analytical study. The values of
APA, Harvard, Vancouver, ISO, and other styles
2

Verma, Akash, Rucha S. Dagaonkar, Dominic Marshall, John Abisheganaden, and R. W. Light. "Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count)." Canadian Respiratory Journal 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/7348239.

Full text
Abstract:
Background. We performed prospective validation of the cancer ratio (serum LDH : pleural ADA ratio), previously reported as predictive of malignant effusion retrospectively, and assessed the effect of combining it with “pleural lymphocyte count” in diagnosing malignant pleural effusion (MPE).Methods. Prospective cohort study of patients hospitalized with lymphocyte predominant exudative pleural effusion in 2015.Results. 118 patients, 84 (71.2%) having MPE and 34 (28.8%) having tuberculous pleural effusion (TPE), were analysed. In multivariate logistic regression analysis, cancer ratio, serum L
APA, Harvard, Vancouver, ISO, and other styles
3

Eruku, Dr Baburao. "Differentiating malignant effusions from other exudative effusions by cancer ratio and cancer ratio plus." International Journal of Advanced Research in Medicine 3, no. 2 (2021): 525–29. http://dx.doi.org/10.22271/27069567.2021.v3.i2h.453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Subhankar Saren, Animesh Mandal, Amit Kumar Das, Ranjit Kumar Haldar, and Sudipta Pandit. "Identifying malignant pleural effusion from tubercular pleural effusion by study of cancer ratio and cancer ratio plus." Asian Journal of Medical Sciences 16, no. 2 (2025): 97–102. https://doi.org/10.71152/ajms.v16i2.4323.

Full text
Abstract:
Background: Early detection of malignant pleural effusions (MPE) through routine biochemical tests will go a long way in improving morbidity and mortality of these patients. Aims and Objectives: The current study was aimed to observe the usefulness of cancer ratio (CR) and CR plus to diagnose malignant effusions early in disease evolution. Materials and Methods: The study was a cross-sectional comparative observational study conducted at the indoor and outdoor facility of Respiratory Medicine department of Institute of Post Graduate Medical Education and Research, Kolkata. Results: Sixty-one p
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Jing-Houng, Yen-Yang Chen, Kwong-Ming Kee, et al. "The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab." Cancers 14, no. 2 (2022): 343. http://dx.doi.org/10.3390/cancers14020343.

Full text
Abstract:
Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5.0 months for the first-line treatment, not reached for the second-line treatment, and 2.5 months fo
APA, Harvard, Vancouver, ISO, and other styles
6

Simon, Michael S., Rowan T. Chlebowski, Jean Wactawski-Wende, et al. "Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality." Journal of Clinical Oncology 30, no. 32 (2012): 3983–90. http://dx.doi.org/10.1200/jco.2012.42.7732.

Full text
Abstract:
Purpose During the intervention phase in the Women's Health Initiative (WHI) clinical trial, use of estrogen plus progestin reduced the colorectal cancer diagnosis rate, but the cancers were found at a substantially higher stage. To assess the clinical relevance of the findings, analyses of the influence of combined hormone therapy on colorectal cancer incidence and colorectal cancer mortality were conducted after extended follow-up. Patients and Methods The WHI study was a randomized, double-blind, placebo-controlled clinical trial involving 16,608 postmenopausal women with an intact uterus w
APA, Harvard, Vancouver, ISO, and other styles
7

Slamon, Dennis J., Patrick Neven, Stephen Chia, et al. "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3." Journal of Clinical Oncology 36, no. 24 (2018): 2465–72. http://dx.doi.org/10.1200/jco.2018.78.9909.

Full text
Abstract:
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 48
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Shu, Minhang Zhou, Peng Wang, et al. "Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis." Technology in Cancer Research & Treatment 21 (January 2022): 153303382211336. http://dx.doi.org/10.1177/15330338221133640.

Full text
Abstract:
Introduction: This retrospective study aimed to compare the efficacy and safety of transarterial chemoembolization plus lenvatinib and programmed death 1 (PD-1) inhibitors versus transarterial chemoembolization plus lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Methods: Consecutive patients with unresectable hepatocellular carcinoma who received transarterial chemoembolization plus lenvatinib and PD-1 inhibitors, lenvatinib, or sorafenib were retrospectively identified in our institution between January 2018 and August 2020. The primary endpoint was overall su
APA, Harvard, Vancouver, ISO, and other styles
9

Bae, Soong June, Chang-Ik Yoon, So Eun Park, et al. "A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): 587. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.587.

Full text
Abstract:
587 Background: The neutrophil to lymphocyte ratio (NLR) has been reported that is associated with response to treatment and prognosis in breast cancer, but its role is unclear in HER2 positive breast cancer. In this study, the relevance of NLR for treatment efficacy was analyzed in HER2 positive breast cancer patients underwent neoadjuvant therapy. Methods: Pre-treatment NLR was assessed in 546 HER2 positive breast cancer patients divided into three groups according to neoadjuvant treatment regimens: i) chemotherapy alone, ii) chemotherapy plus trastuzumab, and iii) chemotherapy plus trastuzu
APA, Harvard, Vancouver, ISO, and other styles
10

Reck, Martin, Alexander Luft, Aleksandra Szczesna, et al. "Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer." Journal of Clinical Oncology 34, no. 31 (2016): 3740–48. http://dx.doi.org/10.1200/jco.2016.67.6601.

Full text
Abstract:
Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods Patients were randomly assigned at a ratio of one to one to receive chemotherapy with etoposide and platinum (cisplatin or carboplatin) plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of four doses each i
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer ratio plus"

1

Nozaki, Shoko, Norie Sawada, Yutaka J. Matsuoka, Ryo Shikimoto, Masaru Mimura, and Shoichiro Tsugane. "Association Between Dietary Fish and PUFA Intake in Midlife and Dementia in Later Life: The JPHC Saku Mental Health Study." In Handbook of Prevention and Alzheimer’s Disease. IOS Press, 2024. http://dx.doi.org/10.3233/aiad230011.

Full text
Abstract:
Background: The relationship between midlife dietary habits and risk of dementia remains unclear. Objective: To investigate the association between dietary fish and n-3 polyunsaturated fatty acid (PUFA) consumption in midlife and risk of dementia in later life. Methods: This population-based cohort study assessed food frequency (average intake in 1995 and 2000) and cognition (2014-2015) in 1,127 participants (aged 45–64 in 1995). We used logistic regression analyses to calculate odds ratios (ORs) for dementia and mild cognitive impairment (MCI) diagnoses for consumption quartiles of fish, PUFA
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer ratio plus"

1

Ozawa, Hiromi, Yoshimasa Miyagawa, Ayako Yanai, et al. "Abstract P3-08-49: Baseline neutrophil-to-lymphocyte ratio and C-reactive protein predict efficacy of bevacizumab plus paclitaxel therapy for locally advanced or metastatic breast cancer." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p3-08-49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Naughton, MJ, BE Schroeder, TN Operana, Y. Zhang, and CA Schnabel. "Abstract P5-08-09: Differential patient stratification by the breast cancer index HoxB13/IL17BR ratio vs recurrence score (RS) plus quantitative ER expression in hormone receptor positive, node negative breast cancer." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p5-08-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vieira, René Aloisio da Costa, Rafael José Fábio Pelorca, and Idam de Oliveira-Junior. "Oncoplastic surgery for Paget’s disease of the breast." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1059.

Full text
Abstract:
Objective: Paget’s disease of the breast (PDB) is a rare nipple entity associated with multifocality. Due to its location, it is necessary to resect the nipple-areolar complex. For surgery, central quadrantectomy, and for mastectomy was the treatment in the past. The feasibility of performing oncoplastic breast surgery (OBS) for PDB is unknown. The objective of this study was to evaluate the feasibility of oncoplastic surgery for Patet’s disease of the breast. Methodology: This retrospective study was approved by the institutional Research Ethics Committee under numbers 657293 and CAAE 3104631
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer ratio plus"

1

Garsa, Adam, Julie K. Jang, Sangita Baxi, et al. Radiation Therapy for Brain Metasases. Agency for Healthcare Research and Quality (AHRQ), 2021. http://dx.doi.org/10.23970/ahrqepccer242.

Full text
Abstract:
Objective. This evidence report synthesizes the available evidence on radiation therapy for brain metastases. Data sources. We searched PubMed®, Embase®, Web of Science, Scopus, CINAHL®, clinicaltrials.gov, and published guidelines in July 2020; assessed independently submitted data; consulted with experts; and contacted authors. Review methods. The protocol was informed by Key Informants. The systematic review was supported by a Technical Expert Panel and is registered in PROSPERO (CRD42020168260). Two reviewers independently screened citations; data were abstracted by one reviewer and checke
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer ratio plus' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography